| Heading: |
Givinostat |
| Question ID: |
1761085 |
| UIN: |
28089 |
| House: |
Commons |
| Date tabled: |
2025-02-03 |
| Asking Member ID: |
4673 |
| Asking Member display name: |
Jo Platt
|
| Asking Member handle: |
JoPlattLeigh
|
| Asking Member Twitter reference: |
@JoPlattLeigh
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NHS England and (b) ITF Pharma UK on the provision of (i) resources and (ii) guidance to NHS trusts to enable them to take part in the Early Access Progr |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-02-10 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
ITF Pharma UK, the United Kingdom marketing authorisation holder for givinostat, is providing access to givinostat through a type of compassionate use scheme called an Early Access Programme (EAP). Under the EAP, givinostat is free to both patients taking... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |